TransMedics CEO sells over $1.1m in company stock

TransMedics Group, Inc. (NASDAQ:TMDX) President and CEO, Waleed H. Hassanein, has sold 12,000 shares of the company's common stock for a total value exceeding $1.1 million, according to a recent SEC filing. The transactions, which took place on April 10, 2024, were executed at a weighted average price of $95.09, with individual sales ranging from $95.00 to $95.54.

The filing also indicated that Hassanein acquired the same number of shares through the exercise of stock options at a price of $13.28 per share, amounting to a total transaction value of $159,360. These transactions were part of a pre-arranged trading plan established on September 6, 2023, under Rule 10b5-1, which allows company insiders to set up a predetermined schedule for buying and selling stocks at a time when they are not in possession of material non-public information.

Following the reported sales, Hassanein's direct ownership in TransMedics stands at 74,087 shares of common stock. Additionally, the SEC filing disclosed that Hassanein indirectly owns 469,359 shares through the Waleed H. Hassanein Revocable Trust. The derivative securities section of the filing showed that after the option exercise, Hassanein has 238,000 options remaining, which are set to vest incrementally each month until fully vested in February 2026.

Investors and market watchers often look to insider buying and selling patterns as a gauge of a company's internal perspective. In this case, the substantial sale by TransMedics' CEO could be of interest to current and prospective shareholders. TransMedics Group, Inc. specializes in electromedical and electrotherapeutic apparatus, providing innovative solutions in the field of organ transplantation.

As TransMedics Group, Inc. (NASDAQ:TMDX) navigates the dynamic field of organ transplantation with cutting-edge technology, its financial metrics and insider transactions provide valuable insights. With a market capitalization of $3.02 billion and an impressive revenue growth of 158.53% over the last twelve months as of Q1 2023, the company is showing a strong expansion in its financial performance.

Despite not being profitable over the last twelve months, an InvestingPro Tip suggests that net income is expected to grow this year, indicating potential for future profitability. This aligns with another InvestingPro Tip that analysts predict the company will be profitable this year, which could be a sign of positive momentum going forward. It's worth noting that the company operates with a moderate level of debt and its liquid assets exceed short-term obligations, providing it with a stable financial footing.

Investors should also consider the stock's volatility, as another InvestingPro Tip highlights that TMDX's stock price movements are quite volatile. This could be relevant for those assessing the risk profile of their investment. Moreover, the company's Price / Book ratio stands at a high 21.95, which may influence valuation considerations.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

For those interested in a deeper analysis, there are 12 additional InvestingPro Tips available, offering further insights into TransMedics Group, Inc.'s financial health and market performance. To access these tips and more, visit https://www.investing.com/pro/TMDX and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.